AAN 2024 | Exploring the use of stem cell therapies for patients with MS

Andrew Wolf, MD, University of Colorado School of Medicine, Aurora, CO, outlines the state of clinical evidence regarding the use of stem cells in multiple sclerosis (MS). Hematopoietic stem cell transplant has been evaluated in a number of smaller trials and retrospective studies and is being compared to highly efficacious disease-modifying agents, such as ocrelizumab, in the large ongoing BEAT-MS (NCT04047628) trial. There is also a growing body of exploratory data from Phase I trials exploring other stem cell therapies. These involve intravenous, intrathecal, or intraventricular administration of stem cell products in the hope that they will have an immunomodulatory effect and reduce inflammation or that they will aid in neuroprotection and regeneration. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.